Zoledronic acid has several advantages over other bisphosphonates. In addition to having broader clinical utility, zoledronic acid can safely be infused over 15 minutes rather than the 2 hours ...

Reclast (zoledronic acid) is a medication that the Food and Drug Administration (FDA) has approved for preventing and treating osteoporosis in females after menopause, males, and individuals who take ...

Reclast (zoledronic acid or zoledronate) is approved by the Food and Drug Administration (FDA) to treat and prevent osteoporosis in males, females after menopause, and people taking glucocorticoids.

EAST HANOVER, N.J., April 11 /PRNewswire/ -- New data show that a once-yearly infusion of Reclast(R) (zoledronic acid) Injection 5mg was significantly better than risedronate at increasing bone mass ...

Zoledronic acid 5 mg/100 mL bottle; solution for IV infusion. Paget’s disease of bone is characterized by greatly increased and disorderly bone remodeling. Excessive osteoclastic bone resorption is ...

- Single infusion of Reclast increases bone mass for two years in postmenopausal women with osteopenia, a condition that can lead to osteoporosis(1) - Approximately 22 million women in US have ...

Once-yearly Reclast Significantly Reduced Bone Fractures in Women with Postmenopausal Osteoporosis Study of over 7,700 women published today shows reduction of 70 percent in spine fractures and 41 ...

The U.S. Food and Drug Administration (FDA) has approved Reclast® (zoledronic acid) Injection, the first and only once-yearly treatment for postmenopausal osteoporosis. Approximately 8 million women ...

Researchers systematically consulted the Massachusetts General Hospital fracture liaison service for patients admitted to the orthopedics service with fragility fracture between February 2016 and ...

Reclast is also indicated to increase bone mass in men with osteoporosis; for the treatment of Paget's disease of bone (men and women); and for the treatment and prevention of glucocorticoid-induced ...

In general, IV bisphosphonates are very well tolerated, and patients rarely require dose modification. In the comparative phase 3 trial of zoledronic acid and pamidronate in patients with breast ...